You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR MERCAPTOPURINE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for MERCAPTOPURINE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Medical Research Council	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	National Cancer Institute (NCI)	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Eastern Cooperative Oncology Group	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002531 ↗	Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia	Unknown status	Johann Wolfgang Goethe University Hospital	Phase 2	1993-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of various combination chemotherapy regimens in treating patients with acute lymphocytic leukemia.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for MERCAPTOPURINE

Condition Name

Chart
Table

Condition Name for MERCAPTOPURINE
Intervention	Trials
Leukemia	62
Acute Lymphoblastic Leukemia	48
Ulcerative Colitis	16
Crohn's Disease	15
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for MERCAPTOPURINE
Intervention	Trials
Leukemia	160
Precursor Cell Lymphoblastic Leukemia-Lymphoma	152
Leukemia, Lymphoid	146
Lymphoma	35
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for MERCAPTOPURINE

Trials by Country

Map
Table

Trials by Country for MERCAPTOPURINE
Location	Trials
Canada	241
Australia	91
Spain	44
France	37
Germany	34
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for MERCAPTOPURINE
Location	Trials
Texas	75
California	68
New York	61
Tennessee	59
Illinois	57
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for MERCAPTOPURINE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for MERCAPTOPURINE
Clinical Trial Phase	Trials
Phase 4	32
Phase 3	86
Phase 2/Phase 3	8
[disabled in preview]	72
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for MERCAPTOPURINE
Clinical Trial Phase	Trials
Completed	120
Recruiting	38
Unknown status	23
[disabled in preview]	23
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MERCAPTOPURINE

Sponsor Name

Chart
Table

Sponsor Name for MERCAPTOPURINE
Sponsor	Trials
National Cancer Institute (NCI)	74
Children's Oncology Group	30
M.D. Anderson Cancer Center	15
[disabled in preview]	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for MERCAPTOPURINE
Sponsor	Trials
Other	332
NIH	81
Industry	67
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.